Develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases
TxCell has raised €11M across 1 funding round from 2 investors, most recently a Growth/Late round in Feb 2017. Based in France; founded 2001; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2017-02-01 | Growth/Late |
| €11M |
| Auriga Partners,Bpifrance |
| View deal → |
